Changchun BCHT Biotechnology

Changchun BCHT Biotechnology EBIT Margin

The EBIT Margin (Operating Margin) of Changchun BCHT Biotechnology (688276.SS) as of Nov 5, 2026 is -61.26 %. In the previous year, EBIT Margin (Operating Margin) was 20.98 % — a change of -391.98% (lower).

EBIT Margin

-61.26 %

YoY

-391.98%

Last updated:

EBIT Margin (Operating Margin) of Changchun BCHT Biotechnology is 2025 -61.26 % . EBIT Margin (Operating Margin) of Changchun BCHT Biotechnology was 2024 20.98 % . It decreases by -391.98% lower compared to the previous year.

For Changchun BCHT Biotechnology, the operating (EBIT) margin of -61.3% is down versus 21.8% a few years ago.

The Changchun BCHT Biotechnology EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
14.67 CNY
Jan 1, 2019
27.46 CNY
Jan 1, 2020
33.68 CNY
Jan 1, 2021
21.79 CNY
Jan 1, 2022
17.45 CNY
Jan 1, 2023
30.65 CNY
Jan 1, 2024
20.98 CNY
Jan 1, 2025
-61.26 CNY
The Changchun BCHT Biotechnology EBIT Margin history
YEAREBIT MarginYoY
-61.26 %-391.98%
20.98 %-31.55%
30.65 %+75.70%
17.45 %-19.93%
21.79 %-35.31%
33.68 %+22.67%
27.46 %+87.22%
14.67 %-11.23%
16.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Changchun BCHT Biotechnology Stock analysis

What does Changchun BCHT Biotechnology do? Changchun BCHT Biotechnology Co. generates revenue through the research and development, production, and sale of human vaccines. The company operates from its headquarters in Changchun, Jilin, and leverages a workforce of 1,252 full-time employees to support its core business activities. Its primary market focus is the domestic market, where it distributes its approved vaccine products to customers seeking prevention and control solutions for infectious diseases. The firm's product portfolio includes three approved vaccines: the varicella vaccine, the rabies vaccine, and the freeze-dried nasal spray flu vaccine. These established products form the basis of its current commercial operations. Additionally, the company is expanding its pipeline with other vaccines under development, alongside a fully human monoclonal antibody also in development, to further address the needs of the infectious disease prevention sector. Changchun BCHT Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Changchun BCHT Biotechnology stock

EBIT Margin (Operating Margin) of Changchun BCHT Biotechnology is -61.26 % in 2025.

EBIT Margin (Operating Margin) of Changchun BCHT Biotechnology changed from 20.98 % to -61.26 %, representing a -391.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Changchun BCHT Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Changchun BCHT Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Changchun BCHT Biotechnology

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Changchun BCHT Biotechnology